[Research progress of epigenetic drug decitabine in AML].

Abstract

Epigenetics is a gene regulation mechanism that can be reversible and heritable, but do not involve the DNA sequence changes. DNA methylation is one of the most important epigenetic modifications, which is closely correlate with tumorigenesis. Decitabine is a methylation inhibitor, which has different action mechanism and targeting characteristics from the traditional chemotherapy, representing a new therapeutic strategy. This review mainly focuses on the anti-leukemia mechanism of decitabine and its clinical efficacy for AML.

• Authors: Rui Zhang, Hui-Min Li
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 22 Issue 5 Pg. 1467-71 (Oct 2014) ISSN: 1009-2137 [Print] China
• PMID: 25338609 (Publication Type: Journal Article, Review)

Chemical References

• Antimetabolites, Antineoplastic
• Decitabine
• Azacitidine

Topics

• Antimetabolites, Antineoplastic (therapeutic use)
• Azacitidine (analogs & derivatives, therapeutic use)
• Cell Transformation, Neoplastic
• DNA Methylation
• Decitabine
• Epigenesis, Genetic
• Humans
• Leukemia, Myeloid, Acute (drug therapy, genetics)